WASHINGTON - Government advisers are scheduled to vote Wednesday on whether a first-of-its-kind HIV drug from Merck & Co. should be approved. The Food and Drug Administration will ask a panel of outside experts whether Merck’s Isentress is safe and effective for HIV patients who have stopped responding to medicines already on the market. The agency is not required to follow the group’s recommendation, though it usually does.
